December 2, 2024 - 18:47

Zscaler, Inc. has announced impressive financial results for the first quarter of fiscal 2025, showcasing significant growth across multiple key metrics. The company's revenue has surged by 26% year-over-year, reaching a total of $628.0 million. This robust growth reflects the increasing demand for Zscaler's cloud-based security solutions in an ever-evolving digital landscape.
In addition to revenue growth, calculated billings also saw a notable increase, rising 13% year-over-year to $516.7 million. This indicates strong customer engagement and a solid pipeline for future revenue. Deferred revenue, a critical indicator of future earnings, grew by 27% year-over-year, totaling $1,783.7 million, further demonstrating the company's ongoing success.
While Zscaler reported a GAAP net loss of $12.1 million, this is a marked improvement compared to a loss of $33.5 million in the same period last year. On a non-GAAP basis, the company achieved a net income of $124.3 million, up from $86.4 million year-over-year, underscoring its operational efficiency and financial health.
June 8, 2026 - 22:27
What history tells us about Marvell's upcoming S&P 500 inclusionMarvell Technology shares have been climbing sharply after the announcement that the company will join the S&P 500 index on June 22. Investors are betting that the move will bring fresh demand from...
June 8, 2026 - 04:51
Is PDD Holdings Inc. (PDD) A Good Stock To Buy Now?A recent discussion on a value investing forum laid out a bullish case for PDD Holdings Inc., the parent company of e-commerce platforms Temu and Pinduoduo. As of late May, shares were trading near...
June 7, 2026 - 03:13
Apple Stock: Buy, Sell, or Hold?Apple`s stock is trading close to an all-time high, and a series of potential catalysts could sustain the upward momentum. The company continues to benefit from strong demand for its latest iPhone...
June 6, 2026 - 22:38
Eli Lilly's $3.8 Billion Vaccine Bets: Here's the Big Story Many Investors Are MissingEli Lilly is making a serious push into the vaccine business. The pharmaceutical giant announced a trio of acquisitions totaling $3.8 billion, aimed at building a new division focused on infectious...